Trial Profile

A Phase II study of Nivolumab plus low dose Ipilimumab as 1st line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Jan 2024 Results of subgroup analysis assessing the relationship between the number of positive MSI markers and the efficacy of NIVO+IPI presented at the 2024 Gastrointestinal Cancers Symposium
24 Oct 2023 Results (Between November 2020 and Aug 2022) assessing the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line therapy in MSI-H advanced gastric or esophagogastric junction cancer patients, presented at the 48th European Society for Medical Oncology Congress.
13 Sep 2022 Trial design presented at the 47th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com